6
60 Degrees Pharmaceuticals Inc
NASDAQ:SXTP
60 Degrees Pharmaceuticals Inc
NASDAQ:SXTP
Price:
1.86
USD
-0.53%
Market Closed
Market Cap:
$4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
6
|
60 Degrees Pharmaceuticals Inc
NASDAQ:SXTP
|
US |
|
Hansard Global PLC
LSE:HSD
|
IM |
|
Kenorland Minerals Ltd
XTSX:KLD
|
CA |
|
Desert Mountain Energy Corp
XTSX:DME
|
CA |
|
Oscar Health Inc
NYSE:OSCR
|
US |
|
C
|
Colruyt Group NV
XBRU:COLR
|
BE |
|
S
|
SFD SA
WSE:SFD
|
PL |
|
Chesapeake Energy Corp
NASDAQ:CHK
|
US |
|
G
|
Great Republic Mining Corp
CNSX:GRM
|
CA |
|
1
|
1369 Construction JSC
VN:C69
|
VN |
|
Singulus Technologies AG
XETRA:SNG
|
DE |
|
V
|
Virgin Wines UK PLC
LSE:VINO
|
UK |
|
Alpek SAB de CV
BMV:ALPEKA
|
MX |
|
IZEA Worldwide Inc
NASDAQ:IZEA
|
US |
|
K
|
Ks Bancorp Inc
OTC:KSBI
|
US |
|
UEX Ltd
TSE:9888
|
JP |
|
Immunovia AB (publ)
STO:IMMNOV
|
SE |
Multiples-Based Value
The Multiples-Based Value of one SXTP stock under the Base Case scenario is hidden USD. Compared to the current market price of 1.86 USD, 60 Degrees Pharmaceuticals Inc is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SXTP Multiples-Based Value
LOCKED
Multiples Across Competitors
SXTP Competitors Multiples
60 Degrees Pharmaceuticals Inc Competitors
60 Degrees Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
6
|
60 Degrees Pharmaceuticals Inc
NASDAQ:SXTP
|
4m USD | 1.4 | -0.2 | -0 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD | 13.6 | 42.8 | 28.9 | 30.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD | 2.6 | 20.7 | 7.9 | 10.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
